In this issue of the ARCHIVES, Wells et al1 present data on the first randomized trial of 2 different formulations of low-molecular-weight heparin (LMWH). The question of whether these compounds are interchangeable is important for the treatment of venous thromboembolism as well as for thromboprophylaxis and treatment of acute coronary syndrome.
Zakarija A, Bennett CL. Low-Molecular-Weight HeparinsDo We Have the GUSTO to Identify Differences Between Alternative Formulations?. Arch Intern Med. 2005;165(7):722-723. doi:10.1001/archinte.165.7.722